Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

General Research Article

The Role of Autophagy and Death Pathways in Dose-dependent Isoproterenolinduced Cardiotoxicity

Author(s): Alexandra Gyongyosi, Rita Zilinyi, Andras Czegledi, Agnes Tosaki, Arpad Tosaki and Istvan Lekli*

Volume 25, Issue 19, 2019

Page: [2192 - 2198] Pages: 7

DOI: 10.2174/1381612825666190619145025

open access plus

Abstract

Background: Isoproterenol (ISO) is a non-selective β-adrenergic agonist. Our aims were to investigate the autophagy and cell death pathways including apoptosis and necrosis in ISO-induced cardiac injury in a dosedependent manner.

Methods: Male Sprague-Dawley rats were treated for 24 hours with I. vehicle (saline); II. 0.005 mg/kg ISO; III. 0.05 mg/kg ISO; IV. 0.5 mg/kg ISO; V. 5 mg/kg ISO; VI. 50 mg/kg ISO, respectively. Hearts were isolated and infarct size was measured. Serum levels of Troponin T (TrT), lactate dehydrogenase (LDH), creatine kinase isoenzyme MB (CK-MB) were measured. TUNEL assay was carried out to monitor apoptotic cell death and Western blot was performed to evaluate the level of autophagic and apoptotic markers.

Results: Survival rate of animals was dose-dependently decreased by ISO. Serum markers and infarct size revealed the development of cardiac toxicity. Level of Caspase-3, and results of TUNEL assay, demonstrated that the level of apoptosis was dose-dependently increased. They reached the highest level in ISO 5 and it decreased slightly in ISO 50 group. Focusing on autophagic proteins, we found that level of Beclin-1 was increased in a dose-dependent manner, but significantly increased in ISO 50 treated group. Level of LC3B-II and p62 showed the same manner, but the elevated level of p62 indicated that autophagy was impaired in both ISO 5 and ISO 50 groups.

Conclusion: Taken together these results suggest that at smaller dose of ISO autophagy may cope with the toxic effect of ISO; however, at higher dose apoptosis is initiated and at the highest dose substantial necrosis occurs.

Keywords: Isoproterenol, cardiotoxicity, necrosis, apoptosis, autophagy, β-adrenergic agonist.

[1]
Lalitha G, Poornima P, Archanah A, Padma VV. Protective effect of neferine against isoproterenol-induced cardiac toxicity. Cardiovasc Toxicol 2013; 13(2): 168-79.
[http://dx.doi.org/10.1007/s12012-012-9196-5] [PMID: 23274852]
[2]
Zhang J, Knapton A, Lipshultz SE, Weaver JL, Herman EH. Isoproterenol-induced cardiotoxicity in sprague-dawley rats: correlation of reversible and irreversible myocardial injury with release of cardiac troponin T and roles of iNOS in myocardial injury. Toxicol Pathol 2008; 36(2): 277-8.
[http://dx.doi.org/10.1177/0192623307313010] [PMID: 18349426]
[3]
Allawadhi P, Khurana A, Sayed N, Kumari P, Godugu C. Isoproterenol-induced cardiac ischemia and fibrosis: Plant-based approaches for intervention. Phytother Res 2018; 32(10): 1908-32.
[http://dx.doi.org/10.1002/ptr.6152] [PMID: 30009418]
[4]
Garg M, Khanna D. Exploration of pharmacological interventions to prevent isoproterenol-induced myocardial infarction in experimental models. Ther Adv Cardiovasc Dis 2014; 8(4): 155-69.
[http://dx.doi.org/10.1177/1753944714531638] [PMID: 24817146]
[5]
Wong ZW, Thanikachalam PV, Ramamurthy S. Molecular understanding of the protective role of natural products on isoproterenol-induced myocardial infarction: A review. Biomed Pharmacother 2017; 94: 1145-66.
[http://dx.doi.org/10.1016/j.biopha.2017.08.009] [PMID: 28826162]
[6]
Agrawal YO, Sharma PK, Shrivastava B, et al. Hesperidin produces cardioprotective activity via PPAR-γ pathway in ischemic heart disease model in diabetic rats. PLoS One 2014; 9(11)e111212
[http://dx.doi.org/10.1371/journal.pone.0111212] [PMID: 25369053]
[7]
Anversa P, Cheng W, Liu Y, Leri A, Redaelli G, Kajstura J. Apoptosis and myocardial infarction. Basic Res Cardiol 1998; 93(Suppl. 3): 8-12.
[http://dx.doi.org/10.1007/s003950050195] [PMID: 9879436]
[8]
Olivetti G, Quaini F, Sala R, et al. Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart. J Mol Cell Cardiol 1996; 28(9): 2005-16.
[http://dx.doi.org/10.1006/jmcc.1996.0193] [PMID: 8899559]
[9]
Lekli I, Haines DD, Balla G, Tosaki A. Autophagy: an adaptive physiological countermeasure to cellular senescence and ischaemia/reperfusion-associated cardiac arrhythmias. J Cell Mol Med 2017; 21(6): 1058-72.
[http://dx.doi.org/10.1111/jcmm.13053] [PMID: 27997746]
[10]
Koleini N, Kardami E. Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity. Oncotarget 2017; 8(28): 46663-80.
[http://dx.doi.org/10.18632/oncotarget.16944] [PMID: 28445146]
[11]
Chen H, Wang X, Tong M, et al. Intermedin suppresses pressure overload cardiac hypertrophy through activation of autophagy. PLoS One 2013; 8(5)e64757
[http://dx.doi.org/10.1371/journal.pone.0064757] [PMID: 23737997]
[12]
Kuzman JA, O’Connell TD, Gerdes AM. Rapamycin prevents thyroid hormone-induced cardiac hypertrophy. Endocrinology 2007; 148(7): 3477-84.
[http://dx.doi.org/10.1210/en.2007-0099] [PMID: 17395699]
[13]
Sengupta A, Molkentin JD, Yutzey KE. FoxO transcription factors promote autophagy in cardiomyocytes. J Biol Chem 2009; 284(41): 28319-31.
[http://dx.doi.org/10.1074/jbc.M109.024406] [PMID: 19696026]
[14]
Lu J, Sun D, Liu Z, et al. SIRT6 suppresses isoproterenol-induced cardiac hypertrophy through activation of autophagy Transl Res 2016; 172: 96-112 e6.
[http://dx.doi.org/10.1016/j.trsl.2016.03.002] [PMID: 27016702]
[15]
Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: Crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007; 8(9): 741-52.
[http://dx.doi.org/10.1038/nrm2239] [PMID: 17717517]
[16]
Kroemer G, Mariño G, Levine B. Autophagy and the integrated stress response. Mol Cell 2010; 40(2): 280-93.
[http://dx.doi.org/10.1016/j.molcel.2010.09.023] [PMID: 20965422]
[17]
Srivastava D, Ivey KN. Potential of stem-cell-based therapies for heart disease. Nature 2006; 441(7097): 1097-9.
[http://dx.doi.org/10.1038/nature04961] [PMID: 16810246]
[18]
MacLellan WR, Schneider MD. Death by design. Programmed cell death in cardiovascular biology and disease. Circ Res 1997; 81(2): 137-44.
[http://dx.doi.org/10.1161/01.RES.81.2.137] [PMID: 9242174]
[19]
Tosaki A, Woodward B, Yamamoto F, Hearse DJ. Isoproterenol and the genesis of reperfusion-induced arrhythmias in isolated rat heart: Adrenoceptor or free radical-mediated mechanisms? J Cardiovasc Pharmacol 1990; 15(3): 398-407.
[http://dx.doi.org/10.1097/00005344-199003000-00009] [PMID: 1691363]
[20]
Gürtler A, Kunz N, Gomolka M, et al. Stain-Free technology as a normalization tool in Western blot analysis. Anal Biochem 2013; 433(2): 105-11.
[http://dx.doi.org/10.1016/j.ab.2012.10.010] [PMID: 23085117]
[21]
Dong RQ, Wang ZF, Zhao C, et al. Toll-like receptor 4 knockout protects against isoproterenol-induced cardiac fibrosis: The role of autophagy. J Cardiovasc Pharmacol Ther 2015; 20(1): 84-92.
[http://dx.doi.org/10.1177/1074248414539564] [PMID: 24950765]
[22]
Brooks WW, Conrad CH. Isoproterenol-induced myocardial injury and diastolic dysfunction in mice: Structural and functional correlates. Comp Med 2009; 59(4): 339-43.
[PMID: 19712573]
[23]
Yen HC, Oberley TD, Vichitbandha S, Ho YS, St Clair DK. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest 1996; 98(5): 1253-60.
[http://dx.doi.org/10.1172/JCI118909] [PMID: 8787689]
[24]
Hadi N, Yousif NG, Al-amran FG, Huntei NK, Mohammad BI, Ali SJ. Vitamin E and telmisartan attenuates doxorubicin induced cardiac injury in rat through down regulation of inflammatory response. BMC Cardiovasc Disord 2012; 12: 63.
[http://dx.doi.org/10.1186/1471-2261-12-63] [PMID: 22867422]
[25]
Mariño G, Niso-Santano M, Baehrecke EH, Kroemer G. Self-consumption: The interplay of autophagy and apoptosis. Nat Rev Mol Cell Biol 2014; 15(2): 81-94.
[http://dx.doi.org/10.1038/nrm3735] [PMID: 24401948]
[26]
Korolchuk VI, Mansilla A, Menzies FM, Rubinsztein DC. Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. Mol Cell 2009; 33(4): 517-27.
[http://dx.doi.org/10.1016/j.molcel.2009.01.021] [PMID: 19250912]
[27]
Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell 2010; 140(3): 313-26.
[http://dx.doi.org/10.1016/j.cell.2010.01.028] [PMID: 20144757]
[28]
Liu WJ, Ye L, Huang WF, et al. p62 links the autophagy pathway and the ubiqutin-proteasome system upon ubiquitinated protein degradation. Cell Mol Biol Lett 2016; 21: 29.
[http://dx.doi.org/10.1186/s11658-016-0031-z] [PMID: 28536631]
[29]
Thomas SH, Behr ER. Pharmacological treatment of acquired QT prolongation and torsades de pointes. Br J Clin Pharmacol 2016; 81(3): 420-7.
[http://dx.doi.org/10.1111/bcp.12726] [PMID: 26183037]
[30]
Grimm D, Elsner D, Schunkert H, et al. Development of heart failure following isoproterenol administration in the rat: Role of the renin-angiotensin system. Cardiovasc Res 1998; 37(1): 91-100.
[http://dx.doi.org/10.1016/S0008-6363(97)00212-5] [PMID: 9539862]
[31]
Shahzad S, Mateen S, Mubeena Mariyath PM, et al. Protective effect of syringaldehyde on biomolecular oxidation, inflammation and histopathological alterations in isoproterenol induced cardiotoxicity in rats. Biomed Pharmacother 2018; 108: 625-33.
[http://dx.doi.org/10.1016/j.biopha.2018.09.055] [PMID: 30245462]

© 2024 Bentham Science Publishers | Privacy Policy